Luciano Rossetti, M.D., has been appointed executive vice president and global head of R&D at Merck KGaA’s biopharmaceutical division, as of July 21st. Dr. Rossetti will be based in Billerica, MA.
 
Dr. Rossetti most recently served as senior vice president of Late Stage Development at Merck Sharp & Dohme, where he was responsible for all clinical development from Phase II – V across all therapeutic areas. He also played a key role in implementing the development strategy of several potential breakthrough compounds such as anti PD-1.
 
“I’m thrilled to welcome Luciano Rossetti to our division,” said Belén Garijo, president and chief executive officer of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. “His breadth of experience and solid track record in both research as well as development together with his distinct leadership profile will be instrumental in driving the development of our promising pipeline to ensure that we will meet our strategic milestones and deliver innovative solutions for unmet medical needs to patients around the world.”